These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34438237)

  • 1. Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis.
    Giustozzi M; Becattini C; Roila F; Agnelli G; Mandalà M
    Cancer Treat Rev; 2021 Nov; 100():102280. PubMed ID: 34438237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.
    Khorana AA; Palaia J; Rosenblatt L; Pisupati R; Huang N; Nguyen C; Barron J; Gallagher K; Bond TC
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors.
    Icht O; Darzi N; Shimony S; Jacobi O; Reinhorn D; Landman Y; Mutai R; Averbuch I; Shochat T; Spectre G; Raanani P; Rotem O; Dudnik E; Peled N; Zer A; Leader A
    J Thromb Haemost; 2021 May; 19(5):1250-1258. PubMed ID: 33605020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of thromboembolic events in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Yang M; Cao H; Wang C; Yu C; Sun P
    J Cancer Res Ther; 2024 Apr; 20(2):509-521. PubMed ID: 38687920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the effect of immune checkpoint inhibitors on venous thromboembolism in non-small cell lung cancer patients.
    He X; Wei SN; Qin WW; Geng N; Li B; Song S; Wang P
    Expert Rev Hematol; 2023; 16(12):1135-1142. PubMed ID: 37883026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Thromboembolic Events in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-analysis of Randomized Controlled Trials.
    Ma Z; Sun X; Zhang Y; Li H; Sun D; An Z; Zhang Y
    Thromb Haemost; 2022 Oct; 122(10):1757-1766. PubMed ID: 35772727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
    Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen H; Han KD; He ZJ; Huang YS
    Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review.
    Solinas C; Saba L; Sganzerla P; Petrelli F
    Thromb Res; 2020 Dec; 196():444-453. PubMed ID: 33065409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Factors of Venous Thromboembolic Disease in Cancer Patients Treated with Immune Checkpoint Inhibitor.
    le Sève JD; Guédon AF; Bordenave S; Agard C; Connault J; Pistorius MA; Quéreux G; Espitia O
    Thromb Haemost; 2023 Nov; 123(11):1049-1056. PubMed ID: 37257835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response rate specific to bone metastasis of various cancers for immune checkpoint inhibitors: a systematic review.
    Tsukamoto S; Mavrogenis AF; Masunaga T; Aiba H; Aso A; Honoki K; Fujii H; Kido A; Tanaka Y; Tanaka Y; Errani C
    Eur J Orthop Surg Traumatol; 2024 Aug; 34(6):2823-2833. PubMed ID: 38836904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction between NSCLC Cells, CD8
    Freitas-Dias C; Gonçalves F; Martins F; Lemos I; Gonçalves LG; Serpa J
    Cells; 2024 Feb; 13(4):. PubMed ID: 38391918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study.
    Deschênes-Simard X; Richard C; Galland L; Blais F; Desilets A; Malo J; Cvetkovic L; Belkaid W; Elkrief A; Gagné A; Hamel MA; Orain M; Joubert P; Ghiringhelli F; Routy B; Blais N
    Thromb Res; 2021 Sep; 205():29-39. PubMed ID: 34246011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy.
    Hill H; Robinson M; Lu L; Slaughter D; Amin A; Mileham K; Patel JN
    Thromb Res; 2021 Dec; 208():71-78. PubMed ID: 34742139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immune-related Adverse Events Induced by ICIs in Advanced NSCLC:
A Meta-analysis and Systematic Review].
    Qin Q; Wang J; Wang H
    Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):772-791. PubMed ID: 32752580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of corticosteroid use on outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Zhang H; Li X; Huang X; Li J; Ma H; Zeng R
    J Clin Pharm Ther; 2021 Aug; 46(4):927-935. PubMed ID: 34138497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors.
    Alma S; Eloi D; Léa V; Julie C; Valérie M; Pierre G; Hilgers W; Philippe G; Christine Z; Philippe D
    J Thromb Thrombolysis; 2022 Aug; 54(2):287-294. PubMed ID: 35396660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials.
    Lin GF; Xu Y; Lin H; Yang DY; Chen L; Huang LL; Su XS; Xu YX; Zeng YM
    Int Immunopharmacol; 2021 Oct; 99():108011. PubMed ID: 34426108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis.
    Wu J; Ni T; Deng R; Li Y; Zhong Q; Tang F; Zhang Q; Fang C; Xue Y; Zha Y; Zhang Y
    Front Immunol; 2023; 14():1065510. PubMed ID: 36993952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.